Publications by authors named "Ada Braun"

Claim this Profile
A
Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone.
Jacob Engellau, Leanne Seeger, Robert Grimer, Robert Henshaw, Hans Gelderblom, Ada Braun

World J Surg Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.
Roger von Moos, Jean-Jacques Body, Blair Egerdie, Alison Stopeck, Janet Brown, Ada Braun

Support Care Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Alison T Stopeck, Karim Fizazi, Jean-Jacques Body, Janet E Brown, Michael Carducci, Ada Braun

Support Care Cancer· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Alison T Stopeck, Karim Fizazi, Jean-Jacques Body, Janet E Brown, Michael Carducci, Ada Braun

Support Care Cancer· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Jean-Jacques Body, Henry G Bone, Richard H de Boer, Alison Stopeck, Catherine Van Poznak, Ada Braun

Eur J Cancer· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
Ingo J Diel, Jean-Jacques Body, Alison T Stopeck, Saroj Vadhan-Raj, Andrew Spencer, Ada Braun

Eur J Cancer· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study.
Javier Martin-Broto, Charles S Cleeland, Paul A Glare, Jacob Engellau, Keith M Skubitz, Ada Braun

Acta Oncol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab for treatment of hypercalcemia of malignancy.
Mimi I Hu, Ilya G Glezerman, Sophie Leboulleux, Karl Insogna, Rasim Gucalp, Ada Braun

J Clin Endocrinol Metab· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing analgesic use in patients with advanced cancer: development of a new scale--the Analgesic Quantification Algorithm.
Karen C Chung, Arie Barlev, Ada H Braun, Yi Qian, Martin Zagari

Pain Med· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health state utilities for skeletal-related events secondary to bone metastases.
Louis S Matza, Karen Chung, Kate Van Brunt, John E Brazier, Ada Braun

Eur J Health Econ· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
Roger von Moos, Jean-Jacques Body, Blair Egerdie, Alison Stopeck, Janet E Brown, Ada Braun

Support Care Cancer· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases.
Louis S Matza, Ze Cong, Karen Chung, Alison Stopeck, Katia Tonkin, Ada Braun

Patient Prefer Adherence· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Araki et al.
Allan Lipton, Karim Fizazi, Alison T Stopeck, David H Henry, Ada H Braun

Eur J Cancer· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
Charles S Cleeland, Jean-Jacques Body, Alison Stopeck, Roger von Moos, Lesley Fallowfield, Ada Braun

Cancer· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
Allan Lipton, Karim Fizazi, Alison T Stopeck, David H Henry, Janet E Brown, Ada Braun

Eur J Cancer· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
Miguel Martin, Richard Bell, Hugues Bourgeois, Adam Brufsky, Ingo Diel, Ada Braun

Clin Cancer Res· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
Carsten Goessl, Leonid Katz, William C Dougall, Paul J Kostenuik, Holly Brenza Zoog, Ada Braun

Ann N Y Acad Sci· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Alison T Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G Steger, Katia Tonkin, Ada Braun

J Clin Oncol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transmembrane and soluble isoforms of heparin-binding epidermal growth factor-like growth factor regulate distinct processes in the pancreas.
Kevin C Ray, Stacy A Blaine, M Kay Washington, Ada H Braun, Amar B Singh

Gastroenterology· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Ada Henrike Braun, Katrin Stark, Olaf Dirsch, Ralf Axel Hilger, Siegfried Seeber

Anticancer Drugs· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trials in oncology: setting standards of care?
Siegfried Seeber, Ada H Braun

Nat Clin Pract Oncol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lysophosphatidic acid, a disintegrin and metalloprotease-17 and heparin-binding epidermal growth factor-like growth factor in ovarian cancer: the first word, not the last.
Ada H Braun, Robert J Coffey

Clin Cancer Res· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New systemic frontline treatment for metastatic colorectal carcinoma.
Ada H Braun, Wolf Achterrath, Hansjochen Wilke, Udo Vanhoefer, Andreas Harstrick

Cancer· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.
Udo Vanhoefer, Mitra Tewes, Federico Rojo, Olaf Dirsch, Norbert Schleucher, Ada H Braun

J Clin Oncol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis